Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.43 |
| ▸ | SYK | P43405 | 9/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8509241 | 0.80 | PTPN11 (0.41) | HSD11B1PTPN11JAK2 | |
| SCHEMBL8509465 | 0.79 | PTPN11 (0.42) | HSD11B1PTPN11 | |
| SCHEMBL8511584 | 0.78 | HSD11B1 (0.41) | HSD11B1PTPN11 | |
| SCHEMBL1159359 | 0.77 | MKNK1 (0.39) | HSD11B1PTPN11 | |
| SCHEMBL974634 | 0.75 | KDM4E (0.47) | HSD11B1PTPN11 | |
| SCHEMBL974412 | 0.74 | HSD11B1 (0.51) | HSD11B1 | |
| SCHEMBL1159894 | 0.74 | PTPN11 (0.37) | HSD11B1PTPN11 | |
| SCHEMBL1160741 | 0.73 | HSD11B1 (0.46) | HSD11B1PTPN11 | |
| SCHEMBL1160146 | 0.73 | PTPN11 (0.37) | HSD11B1PTPN11 | |
| SCHEMBL16239652 | 0.72 | HSD11B1 (0.46) | HSD11B1PTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530473-B2 | Tetrahydroquinoxaline urea derivatives as modulators of 11β-hydroxysteroid dehydrogenase type 1 | SANOFI (FR) | 2013-09-10 | — | — | US | disclosed |
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135958-A1 | TETRAHYDROQUINOXALINE UREA DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CBR3, CBR1, OXGR1 | HSD11B1 1963/4885SYK 1518/4885PTPN11 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.